SoMex Research & Health Organisation

New Scientific News

Indian Journal of Cancer

SoMex Research and Health Organisation assessed the data collection in Immunotherapy in Lung Cancer at BMCHRC.


OVERALL SURVIVAL DATE of PALBOCICLIB presented (TRIO-18) in first line setting.

Benefit of wonder drug DACOMITINIB over GEFATINIB in treatment of advance EGFR positive non small cell lung cancer.

Positive outcome of phase 3 data of trastuzamab with palbociclib.

First line usage of pfizer and e.merck immuno oncology product avelumab plus axitinib.

Successful phase 3 trial results of SUTENT in adjuvent setting.

Efficacy and safety of lorlatinib in ALK positive lung cancer over Crizotinib ceritinib and alectinib.